RT Journal Article
SR Electronic
T1 The U-shaped association of serum iron level with disease severity in adult hospitalized patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.19.21252061
DO 10.1101/2021.02.19.21252061
A1 Kentaro Tojo
A1 Yoh Sugawara
A1 Yasufumi Oi
A1 Fumihiro Ogawa
A1 Takuma Higurashi
A1 Yukihiro Yoshimura
A1 Nobuyuki Miyata
A1 Hajime Hayami
A1 Yoshikazu Yamaguchi
A1 Yoko Ishikawa
A1 Ichiro Takeuchi
A1 Natsuo Tachikawa
A1 Takahisa Goto
YR 2021
UL http://medrxiv.org/content/early/2021/06/10/2021.02.19.21252061.abstract
AB Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that leads to severe respiratory failure (RF). It is known that host exposure to viral infection triggers an iron-lowering response to mitigate pathogenic load and tissue damage. However, the association between host iron-lowering response and COVID-19 severity is not clear. This two-center observational study of 136 adult hospitalized COVID-19 patients analyzed the association between disease severity and initial serum iron, total iron-binding capacity (TIBC), and transferrin saturation (TSAT) levels. Serum iron levels were significantly lower in patients with mild RF than in the non-RF group; however, there were no significant differences in iron levels between the non-RF and severe RF groups, depicting a U-shaped association between serum iron levels and disease severity. TIBC levels decreased significantly with increasing severity; consequently, TSAT was significantly higher in patients with severe RF than in other patients. Multivariate analysis including only patients with RF adjusted for age and sex demonstrated that higher serum iron and TSAT levels were independently associated with the development of severe RF, indicating that inadequate response to lower serum iron might be an exacerbating factor for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors have declared no specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yokohama City University Certified Institutional Review Board Yokohama Municipal Citizen's Hospital Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, [KT], upon reasonable request.ARDSacute respiratory distress syndromeCOVID-19coronavirus disease 2019HFNOhigh-flow nasal oxygen therapyIQRinterquartile rangeMVmechanical ventilationP/F ratioarterial oxygen partial pressure / fractional inspired oxygen ratioRFrespiratory failureSARS-CoV-2severe acute respiratory syndrome coronavirus 2TIBCtotal iron binding capacityTSATtransferrin saturationYCUHYokohama City University HospitalYMCHYokohama Municipal Citizen’s Hospital